Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

  • STATUS
    Not Recruiting
  • participants needed
    12
  • sponsor
    SymBio Pharmaceuticals
Updated on 22 January 2021
Research Site (5.7 mi away) Contact
remission
myelodysplasia
immunosuppressive agents
azacitidine
lenalidomide
hemolysis
blood transfusion

Summary

To assess tolerability of SyB C-1101 when administered orally BID for 21 days followed by a 7-day observation period in patients with recurrent/relapsed or refractory myelodysplastic syndrome in order to determine a recommended dose (RD). To assess safety, efficacy and pharmacokinetics.

Details
Condition Preleukemia, MYELODYSPLASTIC SYNDROME
Treatment SyB C-1101
Clinical Study IdentifierNCT03495167
SponsorSymBio Pharmaceuticals
Last Modified on22 January 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note